Milestone ScientificNYSE American: MLSS

Reports Robust Pipeline of Clinics in Trials Across Multiple States through Partnership with Axial Biologics Reports Robust Pipeline of Clinics in Trials Across Multiple States through Partnership with Axial Biologics

ROSELAND, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Thursday, August 15th, 2024, to discuss the company's financial results for the second quarter ended June 30, 2024, as well as the company's corporate progress and other developments.

ROSELAND, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced a strategic partnership with Axial Biologics, a premier medical device company with a vast distribution network. Under the agreement, Axial Biologics will serve as the distributor of Milestone Scientific's CompuFlo® Epidural System in New Jersey, Texas, and Florida.

ROSELAND, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Novitas Solutions, Inc. (Novitas), a Jurisdictional Medicare Administrative Contractor (JMAC), has granted a Medicare Part B Physician payment rate for the Company's CompuFlo® Epidural System under the American Medical Association's (AMA) technology-specific Category III CPT® code CPT0777T (real-time pressure-sensing epidural guidance system when used in conjunction with a primary ESI procedure).

Brazil is the 9th largest economy in the world with more than  21 million people suffering from chronic back pain

Sales through the new online portal have increased by 31% compared to the same period last year. Gross margin for the first quarter of 2024 has risen to 74.5% from 72.7% for the same period last year. Progress on the reimbursement strategy for the CompuFlo® Epidural System remains steady. Milestone Scientific Inc. (NYSE: MLSS) released this information in a business update and financial results announcement for the first quarter ended March 31, 2024, on May 16, 2024.

Milestone Scientific Inc., a top developer of computerized drug delivery instruments for painless and precise injections, will hold a conference call on May 16, 2024, at 8:30 AM Eastern Time to review financial results for the first quarter of 2024 and discuss corporate advancements and other news.

ROSELAND, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Monday, April 1, 2024, to discuss the company's financial results for 2023, as well as the company's corporate progress and other developments

Milestone Scientific Inc. (NYSE:MLSS ) Q2 2023 Earnings Conference Call August 15, 2023 8:30 AM ET Company Participants David Waldman - Investor Relations Arjan Haverhals - Chief Executive Officer Peter Milligan - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Tucker Andersen - Above All Advisors Operator Greetings, and welcome to the Milestone Scientific Second Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.